Background: Head and neck (H&N) cancers account for about 5% of all malignant tumours.
Pain is one of the most feared consequences of H&N neoplasms and is experienced by up …

Background: Up to now, a transdermal therapeutic system (TTS) of fentanyl has been
applied to cancer patients on opioid analgesics previously treated with mild opioids or …

Cancer patients with relatively stable chronic background pain may experience transient
episodes of pain, known as breakthrough cancer pain (BTP). There is no universally …

Formulations of fentanyl that use buccal, sublingual, or nasal transmucosal routes of
administration have been developed for the treatment of BTP in opioid-tolerant patients with …

Background Three transmucosal fentanyl products have recently been licensed for cancer-
related breakthrough pain: a sublingual tablet, a buccal/sublingual tablet and a nasal spray …

BA CKGROUND: Transdermal therapeutic systems offer potential advantages over oral or
intravenous routes of drug administration. The purpose of this prospective study was to …

Cancer pain is an important challenge in treatment and requires a rapid onset of action for
its control. In particular, breakthrough cancer pain (BTcP) should be adequately controlled …

Meta-analysis could not be performed because of lack of sufficient comparable data.
Numbers needed to treat (NNT) for the analgesic effect could also not be produced. Instead …

Effective pain control is a key factor in cancer management, and is primarily achieved
through drug therapy. Despite the World Health Organization (WHO) guidelines for cancer …

The development of the passive transdermal therapeutic system (TTS) as an effective
method of drug delivery has allowed the potent, lipid soluble opioid fentanyl to be …